psilocybin has been researched along with Inflammation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nichols, CD; Thompson, SM; Wulff, AB | 1 |
| Asghari, S; Cameron, M; Fiselier, A; Gerasymchuk, M; Ghasemi Gojani, E; Groves, A; Haselhorst, L; Hudson, D; Kovalchuk, I; Kovalchuk, O; Li, D; Nandakumar, S; Robinson, GI; Rodriguez-Juarez, R; Snelling, A; Stahl, C; Zanikov, T | 1 |
| Johnson, MW; Nichols, CD; Nichols, DE | 1 |
| Florova, G; Girard, RB; Idell, RD; Idell, S; Komissarov, AA; Shetty, S | 1 |
2 review(s) available for psilocybin and Inflammation
| Article | Year |
|---|---|
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Inflammation; Psilocybin; United States | 2023 |
Psychedelics as Medicines: An Emerging New Paradigm.
Topics: Anxiety; Brain; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; Inflammation; Inflammation Mediators; Lysergic Acid Diethylamide; Mental Disorders; Mind-Body Therapies; Obsessive-Compulsive Disorder; Psilocybin; Psychotherapy; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Substance-Related Disorders | 2017 |
2 other study(ies) available for psilocybin and Inflammation
| Article | Year |
|---|---|
The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cytokines; Encephalitis; Eugenol; Inflammation; Interleukin-6; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Psilocybin; RNA, Messenger; Tumor Necrosis Factor-alpha | 2023 |
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fibrinolysin; Fibrinolysis; Hallucinogens; Humans; Inflammation; Ketamine; Models, Theoretical; Neuropeptides; Neuroserpin; Plasminogen Activator Inhibitor 1; Psilocybin; Receptor, Serotonin, 5-HT2A; Receptors, Urokinase Plasminogen Activator; Serpins; Tissue Plasminogen Activator; United States; Urokinase-Type Plasminogen Activator | 2017 |